Navigation Links
Portrait(R) Plasma - A New Non-Surgical Option for one of the Most Requested Aesthetic Treatment - Aging Eyes
Date:1/24/2008

e dermatological, plastic and cosmetic surgery markets. Plasma energy stimulates a true, natural skin regenerative process that is supported by over 30 completed and ongoing clinical trials. Founded in 2004, Rhytec works with leading dermatologists, plastic surgeons, and cosmetic physicians to develop new technologies that enhance the skin's appearance and function, improving the quality of life for patients seeking treatment. Rhytec, Inc. is privately held, based in Waltham, MA (US), and is a subsidiary of Rhytec, Ltd. in Berkshire (UK).

About Dr. Brian Biesman:

Dr. Brian Biesman received his undergraduate and medical education at the University of Michigan where he graduated with high honors. He completed his Ophthalmology residency at the Illinois Eye and Ear Infirmary before taking fellowship training in Ophthalmic Plastic and Reconstructive Surgery at Manhattan Eye, Ear and Throat Hospital in New York, NY. Upon completion of his fellowship, Dr. Biesman returned to Chicago where he served as Chief Resident.

Dr. Biesman then moved to Boston where he assumed the Directorship of the Eye Plastics and Orbit Service and the Center for Aesthetic Eyelid and Facial Surgery at the New England Medical Center, and was an Assistant Professor of Ophthalmology at Tufts University School of Medicine. Over the next four years he earned faculty appointments in the Division of Otolaryngology at the New England Medical Center and the Divisions of Dermatology and Plastic and Reconstructive Surgery at the Beth Israel-Deaconess Medical Center in Boston. He is currently in private practice in Nashville, TN while holding the academic title of Assistant Clinical Professor at Vanderbilt University Medical Center with faculty appointments in Ophthalmology, Otolaryngology, and Dermatology.

Dr. Biesman has spoken and taught at the local, national and international levels on the topic of aesthetic laser surgery. He has authored many scientific papers and has writte
'/>"/>

SOURCE Rhytec, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. Study Shows Plasma-Derived Human Thrombin Equivalent to Bovine Thrombin in Achieving Hemostasis in Surgery
2. GSK Does Not Option XL784 for Further Development
3. Insmed Provides Update on IPLEX(TM) Expanded Access Program in Italy for the Treatment of Amyotrophic Lateral Sclerosis
4. CeloNova BioSciences Announces Positive Results from European Study of Embozene(TM) Microspheres for Treatment of Uterine Fibroids
5. Childrens Hospital Cancer Study Finds Adolescents and Young Adults Dont Get Same Access to Cutting-Edge Treatment as Younger Patients
6. Arena Pharmaceuticals Announces Positive Phase 1a Clinical Trial Results of APD791 for the Treatment of Arterial Thrombosis and Initiates Phase 1b Clinical Trial
7. Nektar Commences Phase 2 Trial of NKTR-118 (oral PEG-naloxol) Evaluating Efficacy and Safety as Treatment for Opioid-Induced Bowel Dysfunction
8. Watson Announces Positive Results From Its Pivotal Study of Oxybutynin Topical Gel for the Treatment of Overactive Bladder
9. Fovea Pharmaceuticals Receives Orphan Drug Designation from EC for RdCVF for the Treatment of Retinitis Pigmentosa
10. Pharmasset Announces R7128 Achieves 85% Rapid Virologic Response in a 4-week Combination Study for the Treatment of Chronic Hepatitis C
11. AstraZeneca Submits sNDAs for SEROQUEL XR(TM) for the Treatment of Bipolar Mania and Bipolar Depression
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/30/2008)...e-USNewswire/ -- Abnormalities in auditory and lan... autism spectrum disorder by using magnetoencephal...y at the annual meeting of the Radiological Societ...we can record the tiny magnetic fields associated ...rts, Ph.D., vice chair of research in the Departme...
(Date:11/28/2008)...ewswire-FirstCall/ -- Eli Lilly and Company,(NYSE...Application (sNDA) from,the U.S. Food and Drug Ad...),for the management of chronic pain. Lilly plans... 2009, adding data from a recently completed posit...nee. , The decision does not affect duloxet...
(Date:11/26/2008)... Children whose eyes are... increased risk of developing mental illness by ea...inic study published this month in Pediatrics , th...atrics. , , The retrospective study examine...mus (misaligned eyes) and compared them with recor...
(Date:11/26/2008)...ects , , FRANKLIN, Mass., Nov. 26 /PRNewswi...ard: PLCSF) announced today that it has received f...ation (FDA) for its U.S. pivotal trial to study th...(TM) and associated therapy in the prevention of ... FDA also approved PLC,s request to expand their i...
Breaking Medicine Technology:Brain Waves Show Sound Processing Abnormalities in Autistic Children 2Brain Waves Show Sound Processing Abnormalities in Autistic Children 3Lilly Withdraws Application for Additional U.S. Indication for Cymbalta(R) for Chronic Pain 2Lilly Withdraws Application for Additional U.S. Indication for Cymbalta(R) for Chronic Pain 3Lilly Withdraws Application for Additional U.S. Indication for Cymbalta(R) for Chronic Pain 4Eye Divergence in Children Triples Risk of Mental Illness 2PLC Systems Receives Full FDA Approval for Pivotal Study of RenalGuard(TM) in The U.S. 2PLC Systems Receives Full FDA Approval for Pivotal Study of RenalGuard(TM) in The U.S. 3PLC Systems Receives Full FDA Approval for Pivotal Study of RenalGuard(TM) in The U.S. 4Possible biological explanation for C Section linked allergies and asthma found 19976 1Possible biological explanation for C Section linked allergies and asthma found 19976 2Crdentia Announces 2008 First Quarter Results 19972 1Crdentia Announces 2008 First Quarter Results 19972 2Crdentia Announces 2008 First Quarter Results 19972 3Crdentia Announces 2008 First Quarter Results 19972 4Crdentia Announces 2008 First Quarter Results 19972 5Crdentia Announces 2008 First Quarter Results 19972 6Crdentia Announces 2008 First Quarter Results 19972 7FDA Accepts Zingo 28TM 29 Supplemental New Drug Application to Reduce Pain Associated With Peripheral Needle Insertion Procedures in Adults 5547 1FDA Accepts Zingo 28TM 29 Supplemental New Drug Application to Reduce Pain Associated With Peripheral Needle Insertion Procedures in Adults 5547 2FDA Accepts Zingo 28TM 29 Supplemental New Drug Application to Reduce Pain Associated With Peripheral Needle Insertion Procedures in Adults 5547 3FDA Accepts Zingo 28TM 29 Supplemental New Drug Application to Reduce Pain Associated With Peripheral Needle Insertion Procedures in Adults 5547 4Iraq war service 3A A risk factor for bronchiolitis 3F 19967 1Iraq war service 3A A risk factor for bronchiolitis 3F 19967 2
..., FL -- (MARKET WIRE) -- July 06, 2007 -- DOR BioP...://studio.financialcontent.com/Engine?Account=iwir...p://studio.financialcontent.com/Engine?Account=iwi...R" or the "Company") announced today that the Euro...7 B1, with claims related to,oral vaccination usin...
...ublished in The Lancet on TMC125, an Investigation... /PRNewswire/ -- Data from two,ongoing Phase 3 stu... HIV-1 adult patients with documented non-nucleosi...tease inhibitor (PI),resistance reached an undetec...ndetectable level < 50 HIV-1 RNA copies/mL) with,T...
Other Medicine Technology:DOR BioPharma Announces Issuance of European Patent for Its Oral,Multivalent Botulinum Toxin Vaccine BT-VACC 2DOR BioPharma Announces Issuance of European Patent for Its Oral,Multivalent Botulinum Toxin Vaccine BT-VACC 3DOR BioPharma Announces Issuance of European Patent for Its Oral,Multivalent Botulinum Toxin Vaccine BT-VACC 4DOR BioPharma Announces Issuance of European Patent for Its Oral,Multivalent Botulinum Toxin Vaccine BT-VACC 5DOR BioPharma Announces Issuance of European Patent for Its Oral,Multivalent Botulinum Toxin Vaccine BT-VACC 6TMC125 Showed Significant Virologic Response at Week 24 in,Treatment-Experienced HIV Patients With NNRTI Resistance in Phase 3,Trials 2TMC125 Showed Significant Virologic Response at Week 24 in,Treatment-Experienced HIV Patients With NNRTI Resistance in Phase 3,Trials 3TMC125 Showed Significant Virologic Response at Week 24 in,Treatment-Experienced HIV Patients With NNRTI Resistance in Phase 3,Trials 4
(Date:12/1/2008)... 1 This December, Anthem Blue,Cro...he Anthem Blue Cross,HealthFair Bus travels the s...,on Monday, December 1 from the Anthem offices in ...n a multi-city tour to include Los Angeles, Ventur...isco (see detailed schedule,below). , (Pho...
(Date:12/1/2008)...PRNewswire/ -- Question. What would happen if,we ...lding exercise? The,fitness world would certainly...rship fees would have to close. 2. Phony exercise ...t. 3. We would never have to spend another dime on...,s take-home pay is now estimated at 35 billion,d...
(Date:12/1/2008)...D Global Telemedicine, Inc. deploys telemedicine d...t program. 17 school sites in Sevier County, Tenne..., North Chelmsford, MA (PR...dicine & Cherokee Health Systems collaborated ...s in Sevier County, Tennessee. In addition to thi...
(Date:12/1/2008)...stage breast cancer who have undergone breast augm...l-breast radiation treatment called brachytherapy,...l meeting of the Radiological Society of North Ame...ave better cosmetic outcomes and avoid the risk of...ndergo whole-breast radiation therapy. , "We are...
Breaking Medicine News(10 mins):Health News:Anthem Blue Cross Gives the Gift of Health to California 2Health News:Anthem Blue Cross Gives the Gift of Health to California 3Health News:Push-Ups: 'It's Horizontal Jogging' 2Health News:Telemedicine Becoming More Relevant to Children's Health Within School Systems. 2Health News:Telemedicine Becoming More Relevant to Children's Health Within School Systems. 3Health News:Breast cancer treatment offers better outcome to women with implants 2
...2006 issue of General Dentistry, the AGD’s clinica...especially that of the tongue is harmful and shoul...e, the report describes the condition of a young g...was massive scar tissue formation around the area ...
... milk substitute, and a highly vulnerable commodit...ealth concerns determine what goes into formula mi.../ The Codex Alimentarius Commission, part of bot...of the United Nations and the World Health Organis...
...ched a $38 million project along with major region...u threat in Asia and the Pacific. // The Manila-b...e resources urgently needed to help control and re...us, and to increase the region's preparedness for ...
...ons (ASPS) reports say that plastic surgery was pe... The ethnic community opts for this surgery than ...nce their appearance or minimize the signs of agin...nd more people opted for it in the year 2005 with ...
Other Medicine News:
...a national reference laboratory and a worldwide le...ment. ARUP offers an extensive test menu of highly...anatomic pathology. Owned by the University of Uta...lf of the nation's university teaching hospitals a...
...a national reference laboratory and a worldwide le...ment. ARUP offers an extensive test menu of highly...anatomic pathology. Owned by the University of Uta...lf of the nation's university teaching hospitals a...
...a national reference laboratory and a worldwide le...ment. ARUP offers an extensive test menu of highly...anatomic pathology. Owned by the University of Uta...lf of the nation's university teaching hospitals a...
...a national reference laboratory and a worldwide le...ment. ARUP offers an extensive test menu of highly...anatomic pathology. Owned by the University of Uta...lf of the nation's university teaching hospitals a...
Medicine Products: